Nintedanib-13C,d3, a premium pharmaceutical research compound designed for advanced studies in oncology and pulmonary research. As an isotopically labeled analog of Nintedanib, it offers enhanced stability and precise isotopic tracking. Nintedanib-13C,d3 is ideal for use in pharmacological and biochemical research, providing precise and reliable data for your studies. This high-purity compound ensures consistent results, aiding in the development of novel therapies for cancer and pulmonary fibrosis. Trusted by leading laboratories, Nintedanib-13C,d3 is your go-to solution for cutting-edge oncology and pulmonary research. Unlock new possibilities in cancer and lung disease treatment with Nintedanib-13C,d3, where innovation meets reliability.
| Catalog Number | S000239 |
| Molecular Formula | C3013CH30D3N5O4 |
| Purity | 95% |
| IUPAC Name | methyl 2-hydroxy-3-[N-[4-[methyl-[2-[4-(trideuterio(113C)methyl)piperazin-1-yl]acetyl]amino]phenyl]-C-phenylcarbonimidoyl]-1H-indole-6-carboxylate |
| InChI | InChI=1S/C31H33N5O4/c1-34-15-17-36(18-16-34)20-27(37)35(2)24-12-10-23(11-13-24)32-29(21-7-5-4-6-8-21)28-25-14-9-22(31(39)40-3)19-26(25)33-30(28)38/h4-14,19,33,38H,15-18,20H2,1-3H3/i1+1D3 |
| InChIKey | CPMDPSXJELVGJG-KQORAOOSSA-N |
| SMILES | [2H][13C]([2H])([2H])N1CCN(CC1)CC(=O)N(C)C2=CC=C(C=C2)N=C(C3=CC=CC=C3)C4=C(NC5=C4C=CC(=C5)C(=O)OC)O |
| Reference | [1]. Russak EM, et al. Impact of Deuterium Substitution on the Pharmacokinetics of Pharmaceuticals. Ann Pharmacother. 2019;53(2):211-223. [2]. Hilberg F, et al. BIBF 1120: triple angiokinase inhibitor with sustained receptor blockade and good antitumor efficacy. Cancer Res, 2008, 68(12), 4774-4782. [3]. Roth GJ, et al. Design, synthesis, and evaluation of indolinones as triple angiokinase inhibitors and the discovery of a highly specific 6-methoxycarbonyl-substituted indolinone (BIBF 1120). J Med Chem, 2009, 52(14), 4466-4480. |
